Grifols (GIKLY) Cash from Investing Activities (2010 - 2020)

Grifols (GIKLY) reported Cash from Investing Activities of -$125.1 million for Q1 2020, up 56.61% on a YoY basis from -$79.9 million in Q2 2019, and up 71.26% quarter-over-quarter from -$435.2 million in Q4 2019.

Grifols (GIKLY) Cash from Investing Activities (2010 - 2020) Analysis & Trends

Grifols has reported Cash from Investing Activities for 10 years, with the latest figure at -$125.1 million in Q1 2020.

  • For the quarter ending Q1 2020, Cash from Investing Activities rose 56.61% year-over-year to -$125.1 million; the trailing twelve-month figure through Mar 2020 stood at -$94.3 million (down 223.87% YoY), and the FY2025 full-year result was -$674.0 million, down 171.19% from the prior year.
  • Cash from Investing Activities for Q1 2020 stood at -$125.1 million, up from -$435.2 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $2.4 billion in Q4 2017, with the low at -$798.7 million in Q3 2016.
  • Historically, Cash from Investing Activities has averaged $281.0 million across 5 years, with a median of -$120.2 million in 2016.
  • Annual changes were most pronounced in 2016 — Cash from Investing Activities sank 1045.5% — and 2017, when it soared 2116.99%.
  • Grifols' Cash from Investing Activities stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then plunged by 68.9% to $754.2 million in 2018, then slumped by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
  • The last three Cash from Investing Activities figures came in at -$125.1 million (Q1 2020), -$435.2 million (Q4 2019), and -$288.3 million (Q1 2019), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -1.98 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn -3.92 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn -1.04 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -574.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -10.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 1.77 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 785.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn -131.00 Mn
10 Grifols - - - -

Historic Data

Download Data
DateValue
Mar 31, 2020 -125.09 Mn
Mar 31, 2020 -125.09 Mn
Dec 31, 2019 -435.16 Mn
Dec 31, 2019 -435.16 Mn
Mar 31, 2019 -288.25 Mn
Mar 31, 2019 -288.25 Mn
Dec 31, 2018 754.17 Mn
Dec 31, 2018 754.17 Mn
Jun 30, 2018 -509.49 Mn
Jun 30, 2018 -509.49 Mn
Mar 31, 2018 119.73 Mn
Mar 31, 2018 119.73 Mn
Dec 31, 2017 2.43 Bn
Dec 31, 2017 2.43 Bn
Jun 30, 2017 88.45 Mn
Jun 30, 2017 88.45 Mn
Mar 31, 2017 1.98 Bn
Mar 31, 2017 1.98 Bn
Dec 31, 2016 -120.24 Mn
Dec 31, 2016 -120.24 Mn